SEI EXCHANGE TRADED FDS SEI Enhanced Low Volatility U.S. Large Cap ETF SELV 深 沪
等待开盘 08-06 09:30:00 美东时间
30.6621
-0.152
-0.49%
华盛通- 最 高30.88
- 今 开30.88
- 成交量 8001股
- 最 低 30.6621
- 昨 收 30.8139
- 总市值 1.57亿
- 52周最高 31.3617
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 27.4717
- 委 比 0.00%
- 总股本 512.43万
- 历史最高 31.3617
- 量 比 1.61
- 振 幅 0.71%
- 历史最低 20.7036
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palvella Therapeutics Receives U.S. Patent Covering 0.1–20% Anhydrous Compositions Of Rapamycin And Other mTOR Inhibitors
New intellectual property builds on Palvella's multi-layered exclusivity strategyPatent term expected through at least 2038- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical
06-18 19:34
Palvella Therapeutics Receives The Initial Proceeds From A Previously Announced Grant From FDA Office Of Orphan Products Development, The Grant Supports Its Ongoing Phase 3 SELVA trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory expertsUp to $2.6 million in non-dilutive funding anticipated over the grant periodTop-line data
06-09 19:36
Vicor to Present at WCX 2025 in Detroit
How to rapidly implement bi-directional 800V to 48V/12V DC-DC conversion using ...
04-01 21:10
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical com...
2024-07-24 18:30
Rule 8.1 Dealing Disclosure (Horizon Therapeutics Plc)
PDF Version DUBLIN--(BUSINESS WIRE)--Sep. 25, 2023-- IRISH TAKEOVER PANEL D...
2023-09-25 12:00
